•  
  •  
 

Abstract

Case of COVID-19 reinfection are related to immune factors in patients who have recovered by the natural course of the infecting pathogen. However, the chance of COVID-19 reinfection are still not well established. This review aimed to discuss about reinfection-related studies, including causes and clinical manifestations, and reinfection management. Reinfection happens when a patient is infected by the SARS-CoV-2 virus, which has a different genome from previous infection. Although the comparison of clinical manifestation between reinfection and the previous infection is not clear, it is believed that vulnerable populations may have worse outcomes. Vaccination is the main option to reduce the severity of reinfection. Further studies are needed to understand the mechanisms and management of COVID-19 reinfection. Thus, the development of COVID-19 treatment and vaccine can be more effective.

References

1. Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16(10):1753–66. 2. Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress. 2020;4(4):66–75. 3. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):1–10. 4. Keni R, Alexander A, Nayak PG, Mudgal J, Nandakumar K. COVID-19: emergence, spread, possible treatments, and global burden. Front Public Heal. 2020;8:216. 5. He S, Zhou K, Hu M, Liu C, Xie L, Sun S, et al. Clinical characteristics of “re-positive” discharged COVID-19 pneumonia patients in Wuhan, China. Sci Rep. 2020;10(1):1–9. 6. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791–7. 7. Sun Y. Understanding of critical viral and host factors. Vaccine. 2018;35(3):481–8. 8. Martin ET, Kuypers J, Chu HY, Foote S, Hashikawa A, Fairchok MP, et al. Heterotypic infection and spread of rhinovirus a, b, and c among childcare attendees. J Infect Dis. 2018;218(6):848–55. 9. Horby P, Mai LQ, Fox A, Thai PQ, Thi TYN, Thanh LT, et al. The epidemiology of interpandemic and pandemic influenza in Vietnam, 2007-2010. Am J Epidemiol. 2012;175(10):1062–74. 10. Iwasaki A. What reinfections mean for COVID-19. Lancet Infect Dis. 2020;21(1):3–5. 11. Rouchka EC, Chariker JH, Chung D. Variant analysis of 1,040 SARSCoV-2 genomes. PLoS One. 2020;15:1–18. 12. Seyedalinaghi S, Oliaei S, Kianzad S, Afsahi AM, Mohssenipour M, Barzegary A, et al. Reinfection risk of novel coronavirus (COVID-19): a systematic ‎review of current evidence. World J Virol. 2020;9(5):79–90. 13. Richards J, Rivelli A, Fitzpatrick V, Blair C, Copeland K. Incidence of COVID-19 reinfection among Midwestern healthcare employees. PLoS One. 2022;17:1–11. 14. Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, et al. Definitions for COVID-19 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect. 2020;S1198-743X:697–700. 15. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and metaanalysis. Lancet Microbe. 2021;2(1):e13-22. 16. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis. 2020;94:44–8. 17. Lei H, Ye F, Liu X, Huang Z, Ling S, Jiang Z, et al. SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patients. Influenza Other Respi Viruses. 2020;14(6):688– 99. 18. Wang YY, Jin YH, Ren XQ, Li YR, Zhang XC, Zeng XT, et al. Updating the diagnostic criteria of COVID-19 “suspected case” and “confirmed case” is necessary. Mil Med Res. 2020;7(1):17. 19. Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS. Rev Med Virol. 2020;30(3):e2107. 20. Ribero MS, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020;16(7):1–22. 21. Schreiber G. The role of type I interferons in the pathogenesis and treatment of COVID-19. Front Immunol. 2020;11:8–10. 22. Shaha M, Roy B, Akter T, Karim E, Rahaman M. Host immune responses to the infections caused by the infectious viruses. Acta Sci Microbiol. 2018;1(6):13–6. 23. Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20(9):529–36. 24. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv Prepr Serv Heal Sci. 2020;2020:1-20. 25. Rode OĐ, Kurolt IC, Puljiz I, Čivljak R, Balent NC, Laškaj R, et al. Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach. Eur J Clin Microbiol Infect Dis. 2021;40(2):261-8. 26. Liu X, Wang J, Xu X, Liao G, Chen Y, Hu CH. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):1269–74. 27. Carrillo J, Izquierdo-Useros N, Ávila-Nieto C, Pradenas E, Clotet B, Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun. 2020;14(4):337–9. 28. Kang H, Wang Y, Tong Z, Liu X. Retest positive for SARS-CoV-2 RNA of “recovered” patients with COVID-19: persistence, sampling issues, or re-infection? J Med Virol. 2020;92(11):2263–5. 29. İnandıklıoğlu N, Akkoc T. Immune responses to SARS-CoV, MERSCoV and SARS-CoV-2. Adv Exp Med Biol. 2020;1288:5–12. 30. Ko J-H, Joo E-J, Park S-J, Baek JY, Kim WD, Jee J, et al. Neutralizing antibody production in asymptomatic and mild COVID-19 Patients, in comparison with pneumonic COVID-19 patients. J Clin Med. 2020;9(7):2268. 31. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130(10):5235–44. 32. Jiang C, Wang Y, Hu M, Wen L, Wen C, Wang Y, et al. Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Transl Immunol. 2020;9(9):1–14. 33. Lei Q, Li Y, Hou HY, Wang F, Ouyang ZQ, Zhang Y, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2021;76(2):551-61. 34. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARSCoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5(54):1–20. 35. Ali AM, Ali KM, Fatah MH, Tawfeeq HM, Rostam HM. SARSCoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19. New Microbes New Infect. 2021;43:100926. 36. To KKW, Hung IFN, Chan KH, Yuan S, To WK, Tsang DNC, et al. Serum antibody profile of a patient with Coronavirus disease 2019 reinfection. Clin Infect Dis. 2021;72(10):e659–62. 37. Quast I, Tarlinton D. B cell memory: understanding COVID-19. Immunity. 2021;54(2):205–10. 38. Dembrovszky F, Váncsa S, Farkas N, Erőss B, Szakó L, Teutsch B, et al. Immunoglobulin response and prognostic factors in repeated sars-cov-2 positive patients: a systematic review and meta-analysis. Viruses. 2021;13(5):809. 39. Lo Muzio L, Ambosino M, Lo Muzio E, Quadri MFA. Sars-cov-2 reinfection is a new challenge for the effectiveness of global vaccination campaign: A systematic review of cases reported in literature. Int J Environ Res Public Health. 2021;18(20):11001. 40. Tillet RL, Sevinsky JL, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020;21:52–8. 41. Mulder M, van der Vegt DS, Munnink BBO, GeurtsvanKessel CH, van de Bovenkamp J, Sikkema RS, et al. Reinfection of severe acute respiratory syndrome Coronavirus 2 in an immunocompromised patient: a case report. Clin Infect Dis. 2021;73(9):e2841-2. 42. Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B, Wollants E, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis. 2020;2020:1–14. 43. Goldman JD, Wang K, Roltgen K, Nielsen SCA, Roach JC, Naccache SN, et al. Reinfection with SARS-CoV-2 and failure of humoral immunity: a case report. medRxiv Prepr Serv Heal Sci. 2020;98104(206):1–21. 44. Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis. J Med Virol. 2022;94(1):44– 53. 45. Pilz S, Chakeri A, Ioannidis JPA, Richter L, Theiler-Schwetz V, Trummer C, et al. SARS-CoV-2 re-infection risk in Austria. Eur J Clin Invest. 2021;51(4):1–7. 46. Jeffery-Smith A, Rowland TAJ, Patel M, Whitaker H, Iyanger N, Williams SV, et al. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. Lancet Heal Longev. 2021;2(12):e811–9. 47. Iyengar KP, Jain VK, Ish P. COVID-19 reinfection - An enigmatic public health threat. Monaldi Arch Chest Dis. 2020;90(1596):716-7. 48. Jain VK, Iyengar KP, Garg R, Vaishya R. Elucidating reasons of COVID-19 re-infection and its management strategies. Diabetes Metab Syndr Clin Res Rev. 2021;15(3):1001–6. 49. Dao TL, Hoang VT, Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis. 2020;40(1):13-25. 50. Islam MS, Rahman KM, Sun Y, Qureshi MO, Abdi I, Chughtai AA, et al. Current knowledge of COVID-19 and infection prevention and control strategies in healthcare settings: A global analysis. Infect Control Hosp Epidemiol. 2020;41(10):1196–206. 51. Giwa AL, Desai A, Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians. Emerg Med Pract. 2020;22(5):1–28. 52. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Responses to variants after first vaccine dose. Science. 2021;372(6549):1418–23. 53. Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372(6549):1413–8. 54. Boyton RJ, Altmann DM. Risk of SARS-CoV-2 reinfection after natural infection. Lancet. 2021;397(10280):1161–3.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.